Bio-Techne Corp (TECH)

Bio-Techne (NASDAQ: TECH) is currently the target of an acquisition by German life-sciences giant Merck KGaA, Darmstadt, Germany — an all-cash deal worth approximately USD11.3 billion, priced at USD73.00 per share. The deal was announced on 25 June 2026, and Bio-Techne's board has unanimously approved the agreement.

Before we dive into the business details, it's important to frame this correctly: this is not a 'will this stock compound over 5 years' report. It's a merger arbitrage situation — Bio-Techne is being absorbed into Merck, and the real question for investors is whether to hold the stock until deal close to capture the remaining spread, not whether to build a long-term position in it.

What Does Bio-Techne Actually Do?

Bio-Techne is a life-sciences tools company selling protein reagents, antibodies, and diagnostic/spatial-biology products to research labs, large pharmaceutical companies, and hospitals worldwide. The business splits into two main segments:

Large pharma customers have delivered double-digit growth for 6 consecutive quarters — a key reason Merck finds this business attractive: a sticky customer base among the world's largest biopharma players.

📌 Shariah status: Compliant, per Zoya US stock reference.

This section is being refreshed with the latest figures. Please check back soon.

This section is being refreshed with the latest figures. Please check back soon.